Halozyme Therapeutics, Inc. has entered into a definitive agreement to acquire Antares Pharma, Inc.  for approximately $960 million.
 
The combined companies will create a leading drug delivery and specialty product company. The Antares business consists of differentiated, royalty revenue generating auto injector platform business that offers broad licensing opportunity, and a commercial business, with three proprietary commercial products.
 
Financial and Strategic Benefits include: 
 
The transaction is expected to be immediately accretive to Halozyme’s 2022 revenue supported by Antares’ product revenues, royalty revenues and profitability. The addition of Antares is also expected to accelerate growth and enhance cash flow generation through 2027, increasing Halozyme’s flexibility to pursue further growth drivers.
 
The addition of Antares’ commercial products and existing auto injector capabilities accelerate Halozyme’s strategy to drive long-term, durable revenue growth. Halozyme expects to build on Antares’ core platform technology and capabilities to drive revenue opportunities with additional intellectual property protections for Antares technology in place beyond 2030.
 
Antares’ successful development and partnership of its technology platforms offers a widely licensable product suite that can be broadly applied across a spectrum of market segments. This includes the potential for conversion to both high-viscosity and high-volume auto injector devices, supported by Halozyme’s extensive infrastructure and commercially validated ENHANZE platform technology.
 
Antares’ suite of FDA-approved commercial products and partner products utilizing the Antares auto injector technology. The launch of Tlando will leverage existing testosterone commercial infrastructure and capabilities in a growing therapeutic category, building on momentum created by Xyosted’s success.
 
Antares’ differentiated auto injector platform is suitable for use with a broad range of medications. The combined entity will be able to leverage its industry expertise and existing commercial infrastructure in the U.S. to expand delivery capabilities and pursue growth opportunities within multiple small- and large-molecule products.